Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jia Xue
Observed name:
JIA XUE
Institution:
Crown Bioscience (China)
Observed institution:
Crown Bioscience (China)
ORCID:
0000-0002-8048-752X
Observed ORCID:
0000-0002-8048-752X
OpenAlex ID:
A5018292858
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024
·
Hui Yuwen
, Huajing Wang
, et al.
·
Cancer Research
·
21
Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies
2022
·
THILO ZANDER
, JIA XUE
, et al.
·
Anticancer Research
·
3
PDF
Abstract 615: Tim-3 as an immune therapy target, mechanism and action, and prognostic values with its ligands in patient stratification
2022
·
Jia Xue
, Yu Zhang
, et al.
·
Cancer Research
·
1
The molecular similarity landscape of preclinical cancer models to patient tumors
2026
·
Zixuan Xie
, Jia Xue
, et al.
·
JCI Insight
PDF
Abstract 7679: Advanced proteomic profiling of patient-derived tumor models reveals high cross-model concordance and improved translational fidelity
2026
·
Jia Xue
, Hengyuan Liu
, et al.
·
Cancer Research
An NGS-based assay for accurate detection and quantification of immune gene expression in mouse tumor models
2024
·
Jia Xue
, Xiaobo Chen
, et al.
·
PLoS ONE
Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024
·
Hui Yuwen
, Huajing Wang
, et al.
Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024
·
Hui Yuwen
, Huajing Wang
, et al.
Supplementary Table S6 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024
·
Hui Yuwen
, Huajing Wang
, et al.
Supplementary Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024
·
Hui Yuwen
, Huajing Wang
, et al.
Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024
·
Hui Yuwen
, Huajing Wang
, et al.
Supplementary Table S3 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024
·
Hui Yuwen
, Huajing Wang
, et al.
Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024
·
Hui Yuwen
, Huajing Wang
, et al.
Supplementary Table S5 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024
·
Hui Yuwen
, Huajing Wang
, et al.
Abstract A016: Novel LEF1 gene structural variants in T-cell acute lymphoblastic leukemia Patient-Derived Xenografts models
2023
·
Yueying Wang
, Wubin Qian
, et al.
·
Molecular Cancer Therapeutics
Abstract 2053: Structural variants detected by optical genome mapping in acute lymphoblastic leukemia patient-derived xenografts models
2023
·
Yueying Wang
, Mengting Qin
, et al.
·
Cancer Research
40 NGS-based immunology panel: applications in preclinical immuno-oncology research
2022
·
Jia Xue
, Xiaobo Chen
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
17
Citation count:
25
H-index:
2
I10-index:
1
Year
Topic
Type
